March 30 – Chicago Daily Law Bulletin
Prof. Doris Estelle Long authored article
Given the high price of research and development, and the decreasing budgets for health care, innovation in the pharmaceutical industry has become an increasingly troublesome proposition. Even in the best of times, only one in six new drugs makes it successfully through the critical human-testing phase. Worse, drug innovation requires a substantial up-front investment, with no possible return until the new drug has not only proven effective, but received marketing approval from the appropriate government agency.
Read more: Price Wars Undermine Patent Usefulness
